🇺🇸 FDA
Patent

US 9631193

Compositions and methods for inhibiting expression of the ALAS1 gene

granted A61KA61K31/713A61K47/60

Quick answer

US patent 9631193 (Compositions and methods for inhibiting expression of the ALAS1 gene) held by Alnylam Pharmaceuticals, Inc. expires Mon Apr 20 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Alnylam Pharmaceuticals, Inc.
Grant date
Tue Apr 25 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 20 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
45
CPC classes
A61K, A61K31/713, A61K47/60, A61K48/00, A61P